Haemanagiomas

About Haemanagiomas

Hemangiomas are the most common benign vascular tumors of infancy, affecting roughly four to ten percent of children by the age of one year. The risk is higher in low-birth-weight and premature infants, where incidence can reach twenty-three percent. Around sixty percent of hemangiomas occur on the head and neck, twenty-five percent on the trunk and fifteen percent on the limbs. They are not cancers and do not threaten life expectancy. Most parents come to us worried mainly about appearance and growth.

Diagnosis is usually clinical. Dr. Agarwal, FRCS Edinburgh, reviews onset, growth pattern, colour, temperature and any bleeding or ulceration. In most cases, no further investigation is needed. Where lesions are deep, atypical or located in sensitive areas, ultrasound, CT or MRI may be performed to define depth and rule out other diagnoses. Differentiating hemangiomas from low-flow and high-flow vascular malformations is essential, since their treatments differ. A clear diagnosis prevents both over-treatment and under-treatment.

Treatment is individualised. Most uncomplicated hemangiomas are observed, since they regress spontaneously by ten years of age in many children. Medical treatment with oral propranolol or topical timolol can shrink rapidly growing or problematic lesions. Pulsed dye and Nd:YAG lasers help with superficial residual colour or ulcerated lesions, although laser is not the mainstay of treatment. Surgery is reserved for hemangiomas that bleed, cause functional problems or leave a deforming residue once growth has settled.

Surgery in young children is generally avoided where possible, since it can leave more visible scarring than the natural regression would. We typically delay surgical removal until school age, when both psychological impact and operative safety are favourable. For adolescents with residual scars or deformities after a regressed hemangioma, scar revision and reconstructive surgery can refine the area considerably. Throughout the journey, families receive honest counselling about expected growth, regression and the right time to act.

What to expect

• A clinical assessment of onset, growth pattern, location and behaviour
• Targeted imaging with ultrasound or MRI only when needed
• Differentiation from low-flow and high-flow vascular malformations
• An individualised plan, often beginning with observation
• Medical therapy such as propranolol when growth threatens function
• Laser options for superficial residual colour or ulceration
• Surgery reserved for problematic or residual lesions

Recovery

• Most hemangiomas regress over years without active treatment
• Medication courses need monitoring of heart rate, sugar and weight
• Laser sessions may cause brief redness or crusting
• Surgical scars settle over six to twelve months and can be revised
• Photographic follow-up tracks size and colour over time
• Long-term review reassures families through the regression phase